Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 10 to 80

CXCR4-targeted PET/CT to find the source of Cushing's syndrome

Official title: CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study

Run by Peking Union Medical College Hospital · NCT07350707 · Data updated 2026-11-12

This trial will try 68Ga‑Pentixafor (CXCR4) PET/CT scans to help tell apart ACTH-dependent and ACTH-independent Cushing's syndrome and to locate the tumors causing the condition in people with suspected or confirmed Cushing's.

More Cushing Syndrome trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages10 Years to 80 Years
SexAll
Enrollment160 (estimated)
SponsorPeking Union Medical College Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedDecember 25, 2025
Main results expectedNovember 1, 2026
Study endsFebruary 12, 2027
Registry record updatedNovember 3, 2026
Trial IDNCT07350707 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people with suspected or confirmed Cushing's syndrome who can safely undergo PET/CT imaging and provide informed consent.

Probably not a fit

Patients who are pregnant or breastfeeding, allergic to gallium-based tracers, recently received therapeutic radiopharmaceuticals, or are clinically unstable are unlikely to benefit or may be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational effort at Peking Union Medical College Hospital will image patients with suspected or confirmed Cushing's syndrome using 68Ga‑Pentixafor (CXCR4) PET/CT. Imaging results will be compared with conventional modalities and with 68Ga‑DOTATATE PET/CT when available to aid differential diagnosis between ACTH-dependent and ACTH-independent forms and to localize primary lesions. Participants will undergo PET/CT imaging alongside routine biochemical and clinical evaluation, with image findings correlated to clinical reference standards. Performance metrics such as sensitivity, specificity, and localization rates will be reported.

Why it matters

Potential benefit: If successful, this approach could improve the ability to locate disease-causing tumors and clarify the subtype of Cushing's, enabling more targeted treatment decisions.

How similar studies have gone: Previous reports have shown promising diagnostic use of 68Ga‑Pentixafor PET/CT in various neuroendocrine and some ACTH-secreting tumors, but its specific role in Cushing's differential diagnosis is still emerging.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical suspicion or confirmed diagnosis of Cushing's syndrome, based on clinical features (e.g., central obesity, moon face, muscle weakness) and/or abnormal cortisol-related biochemical tests.
* Able and willing to undergo PET/CT imaging with both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE.
* Willing to provide informed consent for participation in the study.

Exclusion Criteria:

* Prior administration of therapeutic or investigational radiopharmaceuticals within 5 physical half-lives before study imaging.

Pregnancy or breastfeeding.

* History of allergic reaction to gallium-based tracers or related compounds.
* Clinically unstable condition or severe organ dysfunction that, in the investigator's opinion, would interfere with PET/CT imaging or study participation.
* Inability to complete both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE PET/CT imaging due to clinical or logistical reasons.

Where it's running

  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.